- Home
- OIO vs KLRS Comparison
OIO vs KLRS Comparison
Compare OIO & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.96
Company Overview
Basic Information| Metric | OIO | KLRS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Cayman Islands | United States |
| Employees | N/A | 20 |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 117.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OIO | KLRS |
|---|---|---|
| Price | $2.16 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 40.8K | ★ 74.4K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $2.14 |
| 52 Week High | $7.50 | $11.88 |
Technical Indicators
Market Signals| Indicator | OIO | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 35.60 |
| Support Level | $1.60 | N/A |
| Resistance Level | $7.50 | $5.48 |
| Average True Range (ATR) | 0.32 | 0.31 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 74.35 | 17.22 |
Price Performance
Historical Comparison OIO
KLRS
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.